<DOC>
	<DOC>NCT01855230</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and clinical activity of ASM-024 administered as a dry powder for inhalation formulation to patients with GOLD 2 or GOLD 3 COPD.</brief_summary>
	<brief_title>Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description>This is a Phase II, randomized, double-blind, placebo-controlled, two-way crossover study to evaluate the safety, tolerability, and clinical activity of a new, dry powder for inhalation formulation of ASM-024 administered twice daily for 14 days to patients with GOLD-2 or GOLD-3 COPD.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Male or female adult aged over 40 yrs with a clinically confirmed diagnosis of COPD at the severity stages of GOLD 2 (moderate) or 3 (severe); Stable COPD for 1 month prior to screening Stable smoker for at least three months prior to screening, or nonsmoker, with a smoking history of ≥ 10 packs years; FEV₁ ≥ 30 % and &lt; 70 % of the predicted normal value; Normal 12lead ECG Clinically significant illness except COPD or surgery within 8 weeks prior to first administration of the study medication; Significant medical history that, in the Investigator's opinion, may adversely affect participation; History of allergy or significant adverse reaction to drugs similar to ASM024, to nicotine, or to cholinergic drugs or any drugs with a similar chemical structure; History of hypersensitivity (anaphylaxis, angioedema) to any drug; Positive pregnancy test for female subjects; Use of medications known to prolong QT/QTc interval; Clinically significant 12 lead ECG at screening; Clinically significant physical examination or laboratory findings or abnormal vital signs; History of alcohol or drug abuse; Positive hepatitis B or C or HIV test at Screening; Investigational drug within 30 days of Screening; longacting investigational drug within 90 days of screening; Previous exposure to ASM024; and Women of childbearing potential and male participants unwilling or unable to use accepted methods of birth control.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>